Abstract:The anticancer activities of Rubia cordifolia and its constituents have been reported earlier, but their influence on the crosstalk of complex cancer-related signaling metabolic pathways (i.e., transcription factors; TF) has not yet been fully investigated. In this study, R. cordifolia root extract was subjected to the cancer signaling assay based bioactivity-guided fractionation, which yielded the following compounds viz., three anthraquinones, namely alizarin (1), purpurin (2), and emodin (3); two lignans, namely eudesmin (4) and compound 5; and two cyclic hexapeptides, namely deoxybouvardin RA-V (6), and a mixture of 6+9 (RA-XXI). The structures of the isolated compounds were determined by NMR spectroscopy and HRESIMS. The isolated compounds 1, 2, 3, 6, and a mixture of 6+9 were tested against a panel of luciferase reporter genes that assesses the activity of a wide-range of cancer-related signaling pathways. In addition, reference anthraquinones viz., chrysophanol (11), danthron (12), quinizarin (13), aloe-emodin (14), and α-lapachone (15) were also tested. Among the tested compounds, the cyclic hexapeptide 6 was found to be very active against several signaling pathways, notably Wnt, Myc, and Notch with IC50 values of 50, 75, and 93 ng/mL, respectively. Whereas, the anthraquinones exhibited very mild or no inhibition against these signaling pathways. Compound 6 being the most active, we tested it for stability in simulated intestinal (SIF) and gastric fluids (SGF), since the stability in biological fluid is a key short-coming of cyclic hexapeptides. The anticancer activity of 6 was found to remain unchanged before and after the treatment of simulated gastric/intestinal fluids, indicating that RA-V was stable. As a result, it could be bioavailable when orally used in therapeutics and possibly a drug candidate for cancer treatment. The mechanism for the preferential inhibition of these pathways and the possible crosstalk effect with other previously reported signaling pathways has been discussed.

Chemical constituents of Rubia tibetica Hook. f. from Tibetan medicine and cytotoxic activity evaluation

Identification of New Compounds from the Roots of Rubia tibetica Hook. f.

A novel flavonoid and other constituents from Rubus rosifolius S.Vidal (Rosaceae)

Isolation of anthraquinone derivatives from Rubia cordifolia (Rubiaceae) and their bioactivities against plant pathogenic microorganisms

Two Novel Anthraquinones with Cytotoxicity from Hedyotis Caudatifolia

Crosstalk of Cancer Signaling Pathways by Cyclic Hexapeptides and Anthraquinones from Rubia cordifolia

Cytotoxic and Antitumor Agents from Genus Rubia

[Chemical Constituents from Roots of Actinidia Rufa and Their Cytotoxicity].

Rubochingosides A - J, labdane-type diterpene glycosides from leaves of Rubus chingii

Chemical constituents from the dish-cultured Antrodia camphorata and their cytotoxic activities

Quinone Derivatives from the Genus Rubia and Their Bioactivities

Discovery of bi-4-methoxycarbonyl-2-quinolone and evaluation of its anti-inflammatory and anti-cancer activity in vitro

Anthraquinones from the Aerial Parts of Rubia cordifolia with Their NO Inhibitory and Antibacterial Activities

Isolation and structure determination of cypritibetquinone A and B, two new phenanthraquinones from Cypripedium tibeticum

Three Sulfur-Containing Natural Products from Rubus Hirsutus Thunb

Two Novel Naphthalene Glucosides and an Anthraquinone Isolated from Rumex dentatus and Their Antiproliferation Activities in Four Cell Lines

A New Rumenic Acid Derivative from the Roots of Cudrania tricuspidata

Constituents from the Roots of Semiaquilegia Adoxoides.

Chemical Constituents from the Roots of Lindera Glauca and Their Antitumor Activity on Four Different Cancer Cell Lines

Phenolic constituents from Rheum nobile and their antioxidant activity

Alashanines A-C, Three Quinone-Terpenoid Alkaloids from Syringa Pinnatifolia with Cytotoxic Potential by Activation of ERK.